Business Monitor International


Malaysia Pharmaceuticals & Healthcare Report

Published 12 December 2013

  • 139 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Malaysia Pharmaceuticals & Healthcare Report

BMI View: Malaysia 's pharmaceutical and healthcare markets continue to show strong growth , and the government ' s 2014 budget allocation for the healthcare sector supports BMI's optimism towards the market. The country 's private healthcare sector is attracting foreign investment and development, which supports the growing medical tourism market. However, the shortage of specialist medical staff and the significant presen ce of counterfeit drugs are issues the country must overcome to avoid them negatively impacting the industry.

Headline Expenditure Projections

  • Pharmaceuticals: MYR6.66bn (US$2.11bn) in 2013 to MYR7.30bn (US$2.28bn) in 2014; +9.6% in local currency and +7.9% in US dollars. Forecast increased in light of new budgetary data for 2014.

  • Healthcare: MYR38.14bn (US$12.11bn) in 2013 to MYR41.98bn (US$13.12bn) in 2014; +10.1% in local currency and +8.4% in US dollars. Forecast raised from Q4 20 13 due to the release of the 2014 budget.

Risk/Reward Rating: In Q2 2014, Malaysia's Pharmaceutical Risk/Reward Rating (RRR) stood at 60, marking no change from Q1 2014. It posts above-average scores for every indicator in the Asia Pacific region, and ranks eighth out of 19 markets.

Key Trends And Developments

February

The recent Arab Health 2014 healthcare exhibition at the Dubai International Exhibition Centre in the UAE helped Malaysian companies to secure sales of MYR215.3mn (US$64.78mn). The most popular products were hospital beds, medical furniture, medical gas pendants, sutures, in vitro medical devices, endotracheal tube, mobile medicine and stem cell treatment, according to the Malaysia External Trade Development Corporation (Matrade). India, Pakistan, Oman, Iran, China, the UAE, Germany, Turkey, Saudi Arabia and Egypt showed interest in importing healthcare products from Malaysia.

Malaysia-based private healthcare chain KPJ Healthcare intends to open two new hospitals in H1 2014 in Malaysia. The company plans to open one hospital in...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceuticals Market Forecast
17
Table: Malaysia Pharmaceutical Sales, Historical Data and Forecasts, 2010-2018
19
Healthcare Market Forecast
20
Table: Healthcare Expenditure Indicators, 2010-2018
21
Table: Healthcare Governmental Indicators 2010-2018
22
Table: Healthcare Private Indicators 2010-2018
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Sales Indicators 2010-2018
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators 2010-2018
26
Generic Drug Market Forecast
27
Table: Generic Drug Sales Indicators 2010-2018
28
OTC Medicine Market Forecast
29
Table: OTC Medicine Sales Indicators 2010-2018
31
Pharmaceutical Trade Forecast
32
Table: Exports And Imports Indicators 2010-2018
34
Other Healthcare Data
36
Key Risks To BMI's Forecast Scenario
37
Macroeconomic Forecasts
39
Table: Malaysia - Economic Activity
43
Industry Risk Reward Ratings
44
Asia Risk/Reward Ratings
44
Malaysia Risk/Reward Ratings
50
Rewards
50
Risks
51
Market Overview
52
Industry Trends And Developments
54
Epidemiology
54
Healthcare Sector
58
Table: 2011 Entry Points Projects Summary
60
Healthcare Insurance
61
Table: Main Features Of 1Care
61
Healthcare Funding
63
Healthcare Sector Developments
64
Table: Public Sector And Private Sector Healthcare Developments
64
Medical Tourism
65
Research & Development
67
Clinical Trials
69
Regulatory Development
71
Regulatory Regime
71
Table: Drug Applications by Type, 2002-10
73
Table: Registered Pharmaceutical Products by Type, 2002-10
73
Regulatory Developments
74
Intellectual Property Issues
78
Pricing Regime
83
Competitive Landscape
85
Domestic Industry
85
Foreign Industry
87
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
89
Culture-Specific Medicines
90
Pharmaceutical Distribution
93
Table: Drug Wholesalers & Importers, 2002-2010
93
Pharmaceutical Retail Sector
93
Company Profile
96
Bumimedic
96
Kotra Pharma
98
Pfizer
101
Pharmaiaga
104
Prime Pharmaceutical
108
Hovid
110
Chemical Company Of Malaysia
114
GlaxoSmithKline
117
Novartis
121
Merck & Co
124
Sanofi
127
Eli Lilly Malaysia
129
Ranbaxy Malaysia
131
Demographic Forecast
133
Table: Malaysia's Population By Age Group, 1990-2020 ('000)
134
Table: Malaysia's Population By Age Group, 1990-2020 (% of total)
135
Table: Malaysia's Key Population Ratios, 1990-2020
136
Table: Malaysia's Rural And Urban Population, 1990-2020
136
Glossary
137
Methodology
139
Pharmaceutical Expenditure Forecast Model
139
Healthcare Expenditure Forecast Model
139
Notes On Methodology
140
Risk/Reward Ratings Methodology
141
Ratings Overview
142
Table: Pharmaceutical Risk/Reward Ratings Indicators
142
Indicator Weightings
143

The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc